Show simple item record

dc.contributor.authorPihlstrøm, Hege
dc.contributor.authorUeland, Thor
dc.contributor.authorMichelsen, Annika
dc.contributor.authorAukrust, Pål
dc.contributor.authorGatti, Francesca
dc.contributor.authorHammarström, Clara Louise
dc.contributor.authorKasprzycka, Monika
dc.contributor.authorWang, Junbai
dc.contributor.authorHaraldsen, Guttorm
dc.contributor.authorMjøen, Geir
dc.contributor.authorDahle, Dag Olav
dc.contributor.authorMidtvedt, Karsten
dc.contributor.authorEide, Ivar Anders
dc.contributor.authorHartmann, Anders
dc.contributor.authorHoldaas, Hallvard
dc.date.accessioned2021-01-20T13:51:10Z
dc.date.available2021-01-20T13:51:10Z
dc.date.issued2020-12-16
dc.description.abstractFollowing a successful renal transplantation circulating markers of inflammation may remain elevated, and systemic inflammation is associated with worse clinical outcome in renal transplant recipients (RTRs). Vitamin D-receptor (VDR) activation is postulated to modulate inflammation and endothelial function. We aimed to explore if a synthetic vitamin D, paricalcitol, could influence systemic inflammation and immune activation in RTRs. Newly transplanted RTRs were included in an open-label randomized controlled trial on the effect of paricalcitol on top of standard care over the first post-transplant year. Fourteen pre-defined circulating biomarkers reflecting leukocyte activation, endothelial activation, fibrosis and general inflammatory burden were analyzed in 74 RTRs at 8 weeks (baseline) and 1 year post-engraftment. Mean changes in plasma biomarker concentrations were compared by t-test. The expression of genes coding for the same biomarkers were investigated in 1-year surveillance graft biopsies (n = 60). In patients treated with paricalcitol circulating osteoprotegerin levels increased by 0.19 ng/ml, compared with a 0.05 ng/ml increase in controls (p = 0.030). In graft tissue, a 21% higher median gene expression level of TNFRSF11B coding for osteoprotegerin was found in paricalcitol-treated patients compared with controls (p = 0.026). Paricalcitol treatment did not significantly affect the blood- or tissue levels of any other investigated inflammatory marker. In RTRs, paricalcitol treatment might increase both circulating and tissue levels of osteoprotegerin, a modulator of calcification, but potential anti-inflammatory treatment effects in RTRs are likely very modest.en_US
dc.identifier.citationPihlstrøm, Ueland, Michelsen, Aukrust, Gatti, Hammarström CL, Kasprzycka, Wang, Haraldsen, Mjøen, Dahle, Midtvedt, Eide, Hartmann, Holdaas. Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients. PLOS ONE. 2020;15:e0273059(12):1-14
dc.identifier.cristinIDFRIDAID 1869027
dc.identifier.doi10.1371/journal.pone.0243759
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/10037/20337
dc.language.isoengen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.journalPLOS ONE
dc.rights.holderCopyright 2020 The Author(s)en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleExploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipientsen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record